These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16442745)

  • 1. The impact of imperfect vaccines on the evolution of HIV virulence.
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Med Hypotheses; 2006; 66(5):907-11. PubMed ID: 16442745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential public health impact of imperfect HIV type 1 vaccines.
    Anderson R; Hanson M
    J Infect Dis; 2005 Feb; 191 Suppl 1():S85-96. PubMed ID: 15627235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
    Blower S; Schwartz EJ; Mills J
    AIDS Rev; 2003; 5(2):113-25. PubMed ID: 12876900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits.
    Elbasha EH; Gumel AB
    Bull Math Biol; 2006 Apr; 68(3):577-614. PubMed ID: 16794946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical study of a staged-progression HIV model with imperfect vaccine.
    Gumel AB; McCluskey CC; van den Driessche P
    Bull Math Biol; 2006 Nov; 68(8):2105-28. PubMed ID: 16868850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imperfect vaccines and the evolution of pathogen virulence.
    Gandon S; Mackinnon MJ; Nee S; Read AF
    Nature; 2001 Dec; 414(6865):751-6. PubMed ID: 11742400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2-sample problem for failure rates depending on a continuous mark: an application to vaccine efficacy.
    Gilbert PB; McKeague IW; Sun Y
    Biostatistics; 2008 Apr; 9(2):263-76. PubMed ID: 17704528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics.
    Owens DK; Edwards DM; Shachter RD
    AIDS; 1998 Jun; 12(9):1057-66. PubMed ID: 9662203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination, within-host dynamics, and virulence evolution.
    André JB; Gandon S
    Evolution; 2006 Jan; 60(1):13-23. PubMed ID: 16568627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the analysis of viral load endpoints in HIV vaccine trials.
    Hudgens MG; Hoering A; Self SG
    Stat Med; 2003 Jul; 22(14):2281-98. PubMed ID: 12854093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the population level effects of an HIV-1 vaccine in an era of highly active antiretroviral therapy.
    Rida W; Sandberg S
    Bull Math Biol; 2009 Apr; 71(3):648-80. PubMed ID: 19214640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the impact of acute infection dynamics on the accumulation of HIV-1 mutations.
    Shiri T; Welte A
    J Theor Biol; 2011 Jun; 279(1):44-54. PubMed ID: 21420419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV vaccines under study.
    Ravanfar P; Mendoza N; Satyaprakash A; Jordan BI
    Dermatol Ther; 2009; 22(2):158-67. PubMed ID: 19335727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadening inclusion of vulnerable populations in HIV vaccine trials.
    Lau CY; Cardinali M; Sato PA; Fix A; Flores J
    Expert Rev Vaccines; 2008 Mar; 7(2):259-68. PubMed ID: 18324894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug induced superinfection in HIV and the evolution of drug resistance.
    Leontiev VV; Maury WJ; Hadany L
    Infect Genet Evol; 2008 Jan; 8(1):40-50. PubMed ID: 18024234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism and history of evolution of symbiotic HIV strains into lethal pandemic strains: the key event may have been a 1927 trial of pamaquine in Leopoldville (Kinshasa), Congo.
    Parris GE
    Med Hypotheses; 2007; 69(4):838-48. PubMed ID: 17368749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imperfect vaccines and the evolution of pathogens causing acute infections in vertebrates.
    Ganusov VV; Antia R
    Evolution; 2006 May; 60(5):957-69. PubMed ID: 16817536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
    Abu-Raddad LJ; Boily MC; Self S; Longini IM
    J Acquir Immune Defic Syndr; 2007 Aug; 45(4):454-67. PubMed ID: 17554215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of virulence in sexually transmitted HIV/AIDS.
    Lipsitch M; Nowak MA
    J Theor Biol; 1995 Jun; 174(4):427-40. PubMed ID: 7666673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.